According to a study led by researchers at Weill Cornell Medicine, an enzyme that protects human cells against viruses may contribute to the progression of cancer into a more malignant state by inducing a variety of mutations in cancer cells. The discovery raises the possibility that the enzyme could serve as a target for upcoming cancer therapies. In the new study, published in Cancer Research journal, scientists used a preclinical model of bladder cancer to investigate the role of the enzyme called APOBEC3G in promoting the disease and found that it significantly increased the number of mutations in tumour cells, boosting the genetic diversity of bladder tumours and hastening mortality.
About the Author
